EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-throughput metabolomics identifies new biomarkers for cervical cancer

Xue Li, Liyi Zhang, Xuan Huang, Qi Peng, Shoutao Zhang, Jiangming Tang, Jing Wang, Dingqing Gui, Fanxin Zeng

Discover Oncology · 29.03.2024 · 15 (1)

DOI: 10.1007/s12672-024-00948-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 29.03.2024. Verfasst von Xue Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, 635000, Sichuan, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Fund of Sichuan health and Health Committee, The Key Projects fund of Science & Technology Department of Sichuan Province, Innovative Scientific Research Project of Medical Youth in Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cervical cancer (CC) is a danger to women’s health, especially in many developing countries. Metabolomics can make the connection between genotypes and phenotypes. It provides a wide spectrum profile of biological processes under pathological or physiological conditions.

Method

In this study, we conducted plasma metabolomics of healthy volunteers and CC patients and integratively analyzed them with public CC tissue transcriptomics from Gene Expression Omnibus (GEO).

Result

Here, we screened out a panel of 5 metabolites to precisely distinguish CC patients from healthy volunteers. Furthermore, we utilized multi-omics approaches to explore patients with stage I-IIA1 and IIA2-IV4 CC and comprehensively analyzed the dysregulation of genes and metabolites in CC progression. We identified that plasma levels of trimethylamine N -oxide (TMAO) were associated with tumor size and regarded as a risk factor for CC. Moreover, we demonstrated that TMAO could promote HeLa cell proliferation in vitro. In this study, we delineated metabolic profiling in healthy volunteers and CC patients and revealed that TMAO was a potential biomarker to discriminate between I-IIA1 and IIA2-IV patients to indicate CC deterioration.

Conclusion

Our study identified a diagnostic model consisting of five metabolites in plasma that can effectively distinguish CC from healthy volunteers. Furthermore, we proposed that TMAO was associated with CC progression and might serve as a potential non-invasive biomarker to predict CC substage. Impact These findings provided evidence of the important role of metabolic molecules in the progression of cervical cancer disease, as well as their ability as potential biomarkers.

Schlagwörter

Stichwörter der Autor:innen

Cervical cancerMetabolitesPrognosisTrimethylamine N-oxide

Autor:innen und Institutionen

  • Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, 635000, Sichuan, China.
  • Department of Gynaecology and Obstetrics, Dazhou Central Hospital, Dazhou, Sichuan, China.
  • Department of Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
  • Department of Clinical Laboratory, Beijing Anding Hospital, Capital Medical University, Beijing, China. ycwangjing@mail.ccmu.edu.cn.
  • Department of Gynaecology and Obstetrics, Dazhou Central Hospital, Dazhou, Sichuan, China. 28459897@qq.com.
  • Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, 635000, Sichuan, China. zengfx@pku.edu.cn.

Förderung

  • Scientific Research Fund of Sichuan health and Health Committee
  • The Key Projects fund of Science & Technology Department of Sichuan Province
  • Innovative Scientific Research Project of Medical Youth in Sichuan Province
  • the Dazhou-Sichuan University Intelligent Medical Laboratory in Dazhou

Zitieren

APA

Li, X., Zhang, L., Huang, X., Peng, Q., Zhang, S., Tang, J., Wang, J., Gui, D., & Zeng, F. (2024). High-throughput metabolomics identifies new biomarkers for cervical cancer. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-00948-8

Vancouver

Li X, Zhang L, Huang X, Peng Q, Zhang S, Tang J, et al. High-throughput metabolomics identifies new biomarkers for cervical cancer. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-00948-8

BibTeX
@article{Li2024,
  author = {Li, Xue and Zhang, Liyi and Huang, Xuan and Peng, Qi and Zhang, Shoutao and Tang, Jiangming and Wang, Jing and Gui, Dingqing and Zeng, Fanxin},
  title = {High-throughput metabolomics identifies new biomarkers for cervical cancer},
  journal = {Discover Oncology},
  year = {2024},
  volume = {15},
  number = {1},
  doi = {10.1007/s12672-024-00948-8}
}
Kostenlos starten →